Deployment
Lingo at Chicago
Lingo is Abbott's over-the-counter continuous glucose monitor biosensor for non-diabetic and wellness consumers, built on the FreeStyle Libre sensor platform, and it is recorded in the biometric form factor as a narrow boundary include and the second glucose example alongside Dexcom Stelo. Made by Abbott, listed on the New York Stock Exchange as ABT through its Abbott Diabetes Care unit, Lingo is a disposable biosensor worn on the back of the upper arm for up to fourteen days using a glucose-oxidase amperometric assay, and it was cleared by the FDA under 510(k) K233655 on May 29, 2024, as a Class II integrated continuous glucose monitoring system for adults eighteen and older who are not on insulin, explicitly not for the diagnosis of any disease including diabetes, a posture directly parallel to Stelo. Its app provides a real-time glucose graph, a Lingo Count daily glucose-spike metric with adaptive targets, food and activity logging, algorithm-driven personalized recommendations, Lingo Challenges behavioral nudges, and Lingo Live sessions with human Abbott nutritionists, with entry pricing of about fifty-four dollars for a two-week single-biosensor starter plan and recurring biweekly and monthly multi-sensor tiers. Glucose is in the biometric definition and Lingo is biometric-primary, and it clears the medical-sensor-without-meaningful-AI exclusion bar on insight-layer substance, since the Lingo Count, adaptive targets, and personalized food-response recommendations are the differentiator versus a bare continuous-glucose graph that Abbott deliberately does not sell to this wellness audience, so the device would exist without the insight layer only in a meaningfully degraded form. A critical cap-flag applies: Lingo is not at parity with Stelo on artificial intelligence. Stelo cleared the bar with a genuine generative-AI layer on Google Cloud Vertex AI and Gemini, whereas Lingo's primary sources describe adaptive and rule-based personalization only, with no documented generative-AI layer and no named AI coaching agent, its coaching being algorithmic plus human nutritionists through Lingo Live, so the registry does not grant Lingo Stelo-equivalent AI standing and records it as the borderline case of the cohort that passes on insight-layer substance rather than on generative-AI grounds. The FDA clearance is the strong anchor, and items not verified include any AI comparable to Stelo's generative AI, a named Lingo coaching agent, the older fifty-three-or-eighty-nine-dollar tier figures since the verified entry is about fifty-four dollars for two weeks and is time-sensitive, and any announced generative-AI roadmap for Lingo.
Lingo by Abbott · Operated by Abbott · Catalog entry · 1 source · not yet field-verified
Machine-readable surfaces
- Markdown mirror: /deployments/abbott-lingo-global-aggregate.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/robots/3a0f3688-2c6c-482c-b8b3-a0cd05d4c12d
- Data documentation: /data
- Query this programmatically: Deploy MCP
Footage
Abbott's introduction of Lingo, its over-the-counter glucose biosensor. Lingo is FDA-cleared OTC (2024) for consumer wellness and metabolic-health tracking, not diabetes medical management, distinct from the prescription FreeStyle Libre.
- Trust tier
- Catalog entry · 1 source · not yet field-verified
- Last updated
- 2026-06-12
- Model
- Lingo
- Company
- Abbott
- Location
- Chicago
- Operator
- Abbott
- Status
- operational
- First seen
- 2024-05-01
- ID
3a0f3688-2c6c-482c-b8b3-a0cd05d4c12d
Sources (1)
- Abbott: FDA authorizes Lingo, first OTC CGM for non-diabetic adults, May 2024 · https://www.abbott.com/corpnewsroom/product-and-innovation/fda-authorizes-lingo-first-otc-cgm.html
Methodology: Verified · 1 source (no primary) · last reviewed 2026-06-12
Verification posture
Verified
Low confidence
Review state
Stable
Last reviewed 2026-06-12
Maturity + lifecycle
Maturity stage: commercial
Lifecycle: active
Architectural position
Cohort: biometric
Sources by quality tier
- 1
- unclassified
- Unclassified source
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Lingo at Chicago.Common questions
- What is the Lingo deployment at Chicago?
- Lingo, built by Abbott, is recorded as a deployment at Chicago on the DEPLOY registry. Abbott operates the deployment directly.
- Who operates Lingo at Chicago?
- Abbott, the manufacturer of Lingo, operates this deployment directly. This is a maker-deploys-its-own-product arrangement rather than a customer pilot.
- When did the Lingo deployment at Chicago go live?
- The deployment is recorded as starting May 1, 2024 on the DEPLOY registry. Earlier activity may exist but is not yet sourced.
- Have there been incidents at the Lingo deployment at Chicago?
- No active incidents affecting this deployment are recorded on the DEPLOY registry. Absence of recorded incidents is not a guarantee no incident occurred; DEPLOY records only sourced incidents and suppresses retracted ones.
Deploy Watch
Track this deployment.
We notify you when status changes against primary-source evidence, contract events surface, or a related incident is filed.